Royalty Pharma plc (NASDAQ: RPRX) stock fell -0.03% on Thursday to $28.76 against a previous-day closing price of $28.77. With 2.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.24 whereas the lowest price it dropped to was $28.69. The 52-week range on RPRX shows that it touched its highest point at $44.47 and its lowest point at $28.45 during that stretch. It currently has a 1-year price target of $48.40. With its current market cap of 17.11 billion, RPRX has annualized dividend of $0.80 while the current yield stands at 2.78%. Beta for the stock currently stands at 0.40.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RPRX was down-trending over the past week, with a drop of -0.35%, but this was down by -3.49% over a month. Three-month performance dropped to -10.54% while six-month performance fell -16.64%. The stock lost -32.50% in the past year, while it has lost -27.23% so far this year. A look at the trailing 12-month EPS for RPRX yields 0.56 with Next year EPS estimates of 3.90. For the next quarter, that number is 0.76. This implies an EPS growth rate of -93.50% for this year and -5.67% for next year. EPS is expected to grow by 4.95% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -45.50%.
Float and Shares Shorts:
At present, 450.40 million RPRX shares are outstanding with a float of 426.87 million shares on hand for trading. On Aug 30, 2023, short shares totaled 8.55 million, which was 1.90% higher than short shares on Jul 30, 2023. In addition to RXRX as the firm’s Recursion Pharmaceuticals, Inc., CPRX serves as its Catalyst Pharmaceuticals, Inc.
Through their ownership of 68.99% of RPRX’s outstanding shares, institutional investors have majority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, RPRX reported revenue of $535.96M and operating income of $377.79M. The EBITDA in the recently reported quarter was $388.41M and diluted EPS was $0.70.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RPRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RPRX analysts setting a high price target of $60.00 and a low target of $40.00, the average target price over the next 12 months is $48.48. Based on these targets, RPRX could surge 108.62% to reach the target high and rise by 39.08% to reach the target low. Reaching the average price target will result in a growth of 68.57% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Dividends & Yield:
In terms of dividends, RPRX has a current ratio of $0.8, which is $0.8 over the trailing 12-months. Dividend yield is another indicator that appeals to many investors, and RPRX currently yields $2.75. In the past year, RPRX’s dividend yield has been $2.75. Accordingly, RPRX has a current buyback yield of $1.04. This was $1.04 for the TTM.